NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $129 million in its fourth quarter.
The Novato, California-based company said it had a loss of $1.29 per share.
The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.20 per share.
The biotechnology company posted revenue of $207 million in the period, topping Street forecasts. Seven analysts surveyed by Zacks expected $202.9 million.
For the year, the company reported a loss of $575 million, or $5.83 per share. Revenue was reported as $673 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE
Copyright © 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
